Last reviewed · How we verify
NCT04126382
LISA vs INSURE in the Treatment of Respiratory Distress Syndrome in Preterm Infants
Phase 2 trial testing Intubate-Surfactant-Extubate(INSURE) in Preterm Infants in 200 participants. Status unknown.
31 December 2024
Quick facts
| Lead sponsor | Anhui Provincial Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 January 2020 |
| Primary completion | 31 December 2024 |
| Estimated completion | 31 December 2024 |
Drugs / interventions tested
- Intubate-Surfactant-Extubate(INSURE)
- less invasive surfactant administration(LISA)
Conditions studied
- Preterm Infants — all drugs for Preterm Infants →
Sponsor
Anhui Provincial Hospital
Who can join
Adults 25 Weeks to 32 Weeks, any sex, with Preterm Infants. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of less invasive surfactant administration（LISA ）technique in the treatment of neonatal respiratory distress syndrome（NRDS） by comparing with the traditional Intubate-Surfactant-Extubate（INSURE） technique.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04126382
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Preterm Infants
Currently open trials in the same condition.
- NCT07522892 — Physiological Safety and Behavioral Comfort of Swaddle Bathing in Preterm Infants · NA · recruiting
- NCT06315556 — An Observational Study to Collect Data on How Aflibercept (Eylea) Given Using a Paediatric Dosing Device is Used in Pret · recruiting
- NCT06092463 — The Intestinal Innate Immune System in Newborns. Development and Inflammation in Health and Disease · recruiting
Other Anhui Provincial Hospital trials
Trials by the same sponsor.
- NCT07523464 — Centrally Confined 8Gy/1f to Tumor Core Followed by Concurrent Chemoradiotherapy for Unresectable Stage III NSCLC · Phase 1 · not yet recruiting
- NCT07481656 — Effects of Recombinant Human Growth Hormone in Elderly Patients With Moderate to Severe Acute Brain Injury (GH-ABI-RCT) · Phase 4 · not yet recruiting
- NCT07462676 — Simultaneous Vs Staged VPS and CP :A Multi-cnter RCT. · NA · not yet recruiting
- NCT07211048 — Anti CD19 Gene Therapy for B-cell Lymphoma · NA · recruiting
- NCT07279844 — An Open-label, Observational, Long-term Follow-up Study Evaluating the Safety and Efficacy of RGL-193 Putamen Injection · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04126382 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Anhui Provincial Hospital
- Last refreshed: 15 October 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04126382.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing